PUBLISHER: The Business Research Company | PRODUCT CODE: 1889516
PUBLISHER: The Business Research Company | PRODUCT CODE: 1889516
Nano antibodies, also known as single-domain antibodies or nanobodies, are small antibody fragments derived from the unique heavy-chain antibodies found in camelids. They maintain the full antigen-binding capability of conventional antibodies but offer greater stability, are easier to produce, and can bind to hidden or hard-to-access epitopes.
The primary products of nano antibodies include single-domain antibodies, heavy-chain antibodies, recombinant nano antibodies, conjugated nano antibodies, and bispecific and multispecific nano antibodies. Single-domain antibodies are small, stable antibody fragments derived from heavy-chain-only antibodies that retain full antigen-binding capacity and are used for therapeutic, diagnostic, and research purposes. They are developed using various technologies, such as phage display technology, recombinant deoxyribonucleic acid (DNA) technology, and molecular cloning, and originate from sources such as animal-derived, recombinant, and plant-derived systems. These antibodies are applied across a wide range of uses, including in vitro disease detection, non-invasive in vivo diagnosis, tumor-targeted therapy, nervous system diseases, circulatory diseases, infectious diseases, and more, and serve end users such as pharmaceutical companies, biotechnology firms, academic and research institutions, and hospitals and diagnostic laboratories.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The nano antibodies market research report is one of a series of new reports from The Business Research Company that provides nano antibodies market statistics, including nano antibodies industry global market size, regional shares, competitors with a nano antibodies market share, detailed nano antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the nano antibodies industry. This nano antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The nano antibodies market size has grown rapidly in recent years. It will grow from $1.55 billion in 2024 to $1.80 billion in 2025 at a compound annual growth rate (CAGR) of 16.4%. The growth in the historic period resulted from the increasing prevalence of chronic and infectious diseases, growing adoption of nanobody-based diagnostic tools, rising research funding in biotechnology and life sciences, expanding use of nanobodies in cancer immunotherapy research, and greater awareness of the advantages of nanoantibodies.
The nano antibodies market size is expected to see rapid growth in the next few years. It will grow to $3.27 billion in 2029 at a compound annual growth rate (CAGR) of 16.0%. The growth in the forecast period will be driven by rising demand for precision and personalized medicine, a growing focus on targeted drug delivery systems, an increasing number of clinical trials for nanobody-based therapies, expanding adoption of nanobody-based imaging agents, and growing commercialization of nanoantibody products. Major trends in the forecast period include the development of novel therapeutic applications of nano antibodies, integration of nano antibodies with nanoparticle drug delivery systems, innovations in multiplexed nano antibody screening technologies, incorporation of biosensor technologies for rapid antibody detection, and the integration of nano antibodies into point-of-care diagnostic devices.
The increasing demand for personalized medicines is expected to drive the growth of the nano antibodies market going forward. Personalized medicines are treatments tailored to an individual's genetic makeup, lifestyle, and environment, ensuring the most effective therapy for each patient. The rising prevalence of chronic and rare diseases is fueling this demand, as these conditions often require targeted, patient-specific therapeutic approaches. Nano antibodies support personalized medicine by providing highly specific, customizable, and targeted solutions aligned with individual patient profiles and disease mechanisms. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, up from six approvals in 2022. Therefore, the growing demand for personalized medicines is driving the expansion of the nano antibodies market.
Companies in the nano antibodies market are focusing on developing advanced therapeutics, including fully multispecific nanobodies, to enhance disease targeting and treatment efficacy. Fully multispecific therapeutics are biologics capable of simultaneously binding to two or more targets, enabling more precise and effective interventions for complex diseases. For example, in February 2023, Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a China-based biopharmaceutical company, launched the Nano 100 Project to develop fully human nanobody therapeutics against over 100 targets. Using Biocytogen's proprietary RenNan mouse platform, the initiative generates fully human nanobodies without requiring humanization. By combining high-throughput in vitro and in vivo screening technologies, the project aims to accelerate target coverage and nanobody drug discovery. These nanobodies demonstrate strong tissue penetration, stability, and engineering flexibility, making them suitable for modalities such as cell therapies, bispecific antibodies, antibody-drug conjugates (ADCs), and radionuclide antibody conjugates. Ultimately, the Nano 100 Project streamlines the development of novel therapeutics for cancer, immune disorders, and neurological diseases.
In September 2024, Valerion Therapeutics LLC, a France-based biotechnology company, acquired Emglev Therapeutics for an undisclosed amount. This acquisition aimed to enhance Valerion's technological capabilities in antibody therapeutics and accelerate its expansion into next-generation immunotherapies. Emglev Therapeutics specializes in single-domain antibodies (sdAbs), also known as nanobodies, further strengthening Valerion's pipeline in advanced antibody-based therapeutics.
Major companies operating in the nano antibodies market are Sanofi S.A., AstraZeneca plc, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Innovent Biologics Inc., GenScript Biotech Corporation, Biocytogen Pharmaceuticals Co. Ltd., Beroni Group Limited., Cusabio Technology LLC, Harbour BioMed Co. Ltd., MoonLake Immunotherapeutics Co. Ltd., Alphamab Oncology Co. Ltd., Santa Cruz Biotechnology Inc., Rockland Immunochemicals Inc., Creative Biolabs Inc., Promab Biotechnologies Inc., ExeVir Bio N.V., Isogenica Ltd., Allele Biotechnology And Pharmaceuticals Inc., Gulliver Biomed Inc., Capralogics Inc.
North America was the largest region in the nano antibodies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in nano antibodies report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the nano antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The nano antibodies market consists of sales of nano antibody constructs, diagnostic reagents, therapeutic formulations, assay kits, and research-grade antibody products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Nano Antibodies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on nano antibodies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for nano antibodies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The nano antibodies market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.